These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26145831)

  • 1. Bayesian evaluation of a physiologically-based pharmacokinetic (PBPK) model of long-term kinetics of metal nanoparticles in rats.
    Sweeney LM; MacCalman L; Haber LT; Kuempel ED; Tran CL
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):151-63. PubMed ID: 26145831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian population analysis of a washin-washout physiologically based pharmacokinetic model for acetone.
    Mörk AK; Jonsson F; Johanson G
    Toxicol Appl Pharmacol; 2009 Nov; 240(3):423-32. PubMed ID: 19660484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian evaluation of a physiologically based pharmacokinetic (PBPK) model for perfluorooctane sulfonate (PFOS) to characterize the interspecies uncertainty between mice, rats, monkeys, and humans: Development and performance verification.
    Chou WC; Lin Z
    Environ Int; 2019 Aug; 129():408-422. PubMed ID: 31152982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models.
    Hack CE
    Toxicology; 2006 Apr; 221(2-3):241-8. PubMed ID: 16466842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of Bayesian population physiologically based pharmacokinetic (PBPK) modeling and Markov chain Monte Carlo simulations to pesticide kinetics studies in protected marine mammals: DDT, DDE, and DDD in harbor porpoises.
    Weijs L; Yang RS; Das K; Covaci A; Blust R
    Environ Sci Technol; 2013 May; 47(9):4365-74. PubMed ID: 23560461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Markov chain Monte Carlo analysis to biomathematical modeling of respirable dust in US and UK coal miners.
    Sweeney LM; Parker A; Haber LT; Tran CL; Kuempel ED
    Regul Toxicol Pharmacol; 2013 Jun; 66(1):47-58. PubMed ID: 23454101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifetime PCB 153 bioaccumulation and pharmacokinetics in pilot whales: Bayesian population PBPK modeling and Markov chain Monte Carlo simulations.
    Weijs L; Roach AC; Yang RS; McDougall R; Lyons M; Housand C; Tibax D; Manning T; Chapman J; Edge K; Covaci A; Blust R
    Chemosphere; 2014 Jan; 94():91-6. PubMed ID: 24080004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites.
    Hack CE; Chiu WA; Jay Zhao Q; Clewell HJ
    Regul Toxicol Pharmacol; 2006 Oct; 46(1):63-83. PubMed ID: 16889879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition.
    Nong A; Tan YM; Krolski ME; Wang J; Lunchick C; Conolly RB; Clewell HJ
    J Toxicol Environ Health A; 2008; 71(20):1363-81. PubMed ID: 18704829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
    Marino DJ; Clewell HJ; Gentry PR; Covington TR; Hack CE; David RM; Morgott DA
    Regul Toxicol Pharmacol; 2006 Jun; 45(1):44-54. PubMed ID: 16442684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian population physiologically-based pharmacokinetic model for robustness evaluation of withdrawal time in tilapia aquaculture administrated to florfenicol.
    Lin HC; Chen WY
    Ecotoxicol Environ Saf; 2021 Mar; 210():111867. PubMed ID: 33387907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age.
    Allen BC; Hack CE; Clewell HJ
    Risk Anal; 2007 Aug; 27(4):947-59. PubMed ID: 17958503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and evaluation of a harmonized physiologically based pharmacokinetic (PBPK) model for perchloroethylene toxicokinetics in mice, rats, and humans.
    Chiu WA; Ginsberg GL
    Toxicol Appl Pharmacol; 2011 Jun; 253(3):203-34. PubMed ID: 21466818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian calibration of process-based forest models: bridging the gap between models and data.
    Van Oijen M; Rougier J; Smith R
    Tree Physiol; 2005 Jul; 25(7):915-27. PubMed ID: 15870058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction uncertainty assessment of chromatography models using Bayesian inference.
    Briskot T; Stückler F; Wittkopp F; Williams C; Yang J; Konrad S; Doninger K; Griesbach J; Bennecke M; Hepbildikler S; Hubbuch J
    J Chromatogr A; 2019 Feb; 1587():101-110. PubMed ID: 30579636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.
    Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L
    PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach.
    Chiu WA; Okino MS; Evans MV
    Toxicol Appl Pharmacol; 2009 Nov; 241(1):36-60. PubMed ID: 19660485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers.
    Wedagedera JR; Afuape A; Chirumamilla SK; Momiji H; Leary R; Dunlavey M; Matthews R; Abduljalil K; Jamei M; Bois FY
    CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):755-765. PubMed ID: 35385609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBTK model for assessment of operator exposure to haloxyfop using human biomonitoring and toxicokinetic data.
    Cooper AB; Aggarwal M; Bartels MJ; Morriss A; Terry C; Lord GA; Gant TW
    Regul Toxicol Pharmacol; 2019 Mar; 102():1-12. PubMed ID: 30543831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based modeling of the inhalation kinetics of styrene in humans using a bayesian population approach.
    Jonsson F; Johanson G
    Toxicol Appl Pharmacol; 2002 Feb; 179(1):35-49. PubMed ID: 11884235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.